Milestone Pharmaceuticals resubmits NDA for etripamil nasal spray to FDA for PSVT

Milestone Pharmaceuticals Inc.

NDA resubmission for self-administered etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT).
Resubmission follows FDA Type A meeting after a Refusal to File letter; no new efficacy/safety data requested.
Package includes restructured AE timing data and reformatted data files to facilitate FDA review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.